LIST OF TABLES

Table 2.1	Comparison of some routes for systemic delivery	15
Table 2.2	Characteristics of Different Regions of Oral Mucosa and Their Suitability for Buccal Deliver	18
Table 2.3.	Buccal penetration enhancers	28
Table 2.4	Reports citing use of enhancers in buccal permeation enhancement	29
Table 2.5.	Drug and formulation factors affecting systemic absorption of drugs via the oral mucosa.	32
Table 2.6	Commercial buccal adhesive drug delivery systems	34
Table 2.7.	Summary of research work on buccal adhesive tablets	35
Table 2.8	Summary of research work on buccal bioadhesive gels	36
Table 2.9	Summary of research work on buccal adhesive patches/films	37
Table2.10.	Absorption spectra of Methotrexate.	50
Table 2. 11	Typical Poloxamer grades	58
Table 2.12.	Uses of Poloxamer	59
Table.2.13	Solubility at 25°C for various types of poloxamer in different solvents.	60
Table 2.14.	Uses and typical concentrations of ethylcellulose.	61
Table 2.15	Chemical name for poly(methylvinyl ether/maleic anhydride) copolymers and derivatives	65
Table 2.16.	Molecular weights of selected commercially available copolymers of poly(methylvinyl ether/maleic anhydride)	66
Table 2.17.	Gantrez Copolymers Typical Applications (ISP Technical literature, 2003)	66
Table 2.18.	Structural formula and molecular weight of polyethylene glycol polymers	69
Table 2.19.	Solubility of Lactose.	72

Table 3.1	Calibration curve for FU in phosphate buffer (pH 6.8)	100
Table 3.2	Parameters for UV spectrometric method of analysis for FU.	101
Table 3.3	Intraday precision and accuracy for the FU assay by UV spectroscopy.	102
Table 3.4	Interday variability of FU assay by UV spectroscopy over 3 consecutive days.	102
Table 3.5.	Calibration curve for FU in plasma by HPLC	105
Table 3.6	Parameters for HPLC method for estimation of FU in plasma.	107
Table 3.7	Intraday precision and accuracy for FU plasma samples.	108
Table 3.8	Interday precision and accuracy of FU assay by HPLC over 3 consecutive days	108
Table 3.9	Extraction efficiency of FU from rabbit plasma at various concentrations.	109
Table 3.10	Calibration curve values for MTX in phosphate buffer pH 6.8	111
Table 3.11.	Parameters for UV spectrometric method for analysis of MTX	112
Table 3.12	Intraday precision and accuracy for the MTX assay by UV spectroscopy.	113
Table 3.13.	Interday variability of MTX assay by UV spectroscopy over 3 consecutive days.	113
Table 3.14.	Calibration curve of MTX in plasma by HPLC.	116
Table 3.15.	Parameters for HPLC method for estimation of MTX in plasma.	117
Table 4.1.	List of materials	120
Table.4.2.	Compositions for mucoadhesive layer	124
Table.4.3.	Compositions for protective layer	124
Table 4.4.	Preliminary batches for FU tablets	130
Table 4.5.	Factor combinations as per 3^2 factorial design	131

Table 4.6	Compositions of the FU Bioadhesive Gel Formulations (%w/w)	136
Table 5.1.	Permeability of FU across buccal mucosa in presence of penetration enhancers	149
Table 5.2.	Influence of glycerine plasticization on the bioadhesive strength and tensile strength	150
Table 5.3.	Physicochemical parameters of FU containing mucoadhesive patches.	152
Table 5.4.	Release Kinetics of 5-Fluorouracil containing bioadhesive Patches	160
Table 5.5.	Characteristic XRD peaks of FU and its physical mixture with patch components and patch	163
Table 5.6	Stability results for FU bioadhesive patches.	163
Table 5.7.	Mean values of percent cumulative drug released for the FU bioadhesive formulations prepared during pre-optimization studies	167
Table 5.8	Physical characterization and drug assay for preliminary batches of FU tablets	167
Table 5.9.	Physical characterization and drug assay for FU tablets	169
Table 5.10.	Response parameters for formulations of bilayered buccal tablets prepared as per 32 factorial design.	171
Table 5.11.	Observed and Predicted values of response parameters	172
Table 5.12.	Multiple Regression Output for Dependent Variables	182
Table 5.13.	Results of Analysis of Variance (ANOVA) for measured responses	183
Table 5.14.	The predicted and observed response variables of the optimal FU buccal bioadhesive tablets	184
Table 5.15.	Stability results for FU bioadhesive tablets	189
Table 5.16.	pH and Assay of FU bioadhesive gel formulations	191
Table 5.17	Release Kinetics of 5-Fluorouracil containing bioadhesive gels	196
Table 5.18.	Characteristic XRD peaks of FU and its physical mixture	202

	and solid dispersions with polymers	
Table 5.19.	Characteristic DSC peaks of FU and its physical mixture and solid dispersions with polymers	204
Table 5.20.	Stability results of FU bioadhesive gels	207
Table 5.21.	Mean plasma concentration (ng/ml) of FU from the oral, IV and buccal mucoadhesive administration of FU formulations.	213
Table5.22.	Pharmacokinetic Characteristics of FU after Oral Administration of Conventional Tablet, Intravenous injection and Application of Buccoadhesive formulations (Patch, Tablet, Gel) in Rabbits.	214
Table 6.1.	Compositions for mucoadhesive layer	220
Table 6.2.	Compositions for protective layer	220
Table 6.3.	Preliminary batches for MTX tablets	224
Table 6.4.	Factor combinations as per 3^2 factorial design	225
Table 6.5.	Compositions of the MTX bioadhesive gel formulations (%w/w)	229
Table 7.1.	Permeability of MTX across buccal mucosa in presence of penetration enhancers	238
Table 7.2	Physicochemical parameters of MTX mucoadhesive patches	240
Table 7.3	Release kinetics of MTX bioadhesive Patches	246
Table 7.4.	Characteristic XRD peaks of MTX and its physical mixture with patch components and patch	249
Table 7.5.	Stability results for MTX bioadhesive patches	252
Table 7.6.	Mean values of percent cumulative drug released for the MTX bioadhesive tablets prepared during preliminar studies	253
Table 7.7.	Physical parameters and drug assay for preliminary batches of MTX tablets (PMT1-PMT5)	254
Table 7.8.	Physical characterization and drug assay for MTX tablets	255
Table 7.9.	Response parameters for formulations of MTX bilayered	256

buccal tablets prepared as per 32 factorial design

Table 7.10.	Observed and Predicted values of response parameters for Methotrexate bioadhesive tablets.	257
Table 7.11.	Multiple regression output for Dependent variables	269
Table 7.12.	Results of analysis of variance (ANOVA) for measured response	270
Table 7.13.	The predicted and observed response variables of the optimal MTX buccal bioadhesive tablets	271
Table 7.14.	Stability results for MTX bioadhesive tablets	274
Table 7.15.	pH and Assay of MTX bioadhesive gel formulations	279
Table 7.16.	Release Kinetics of MTX containing bioadhesive gels	283
Table 7.17.	Characteristic XRD peaks of MTX and its physical mixture and solid dispersions with polymers	289
Table 7.18.	Stability results of MTX bioadhesive gels	293
Table 7.19.	Mean plasma concentration (ng/ml) of MTX from the oral, IV and administration of MTX buccal mucoadhesive formulations.	298
Table 7.20.	Pharmacokinetic Characteristics of MTX after Oral Administration of Conventional Tablet, Intravenous injection and Application of Buccoadhesive formulations (Patch, Tablet, Gel) in Rabbits.	299